These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
688 related articles for article (PubMed ID: 17213019)
21. Biological characteristics of neuroblastoma with partial deletion in the short arm of chromosome 1. Hiyama E; Hiyama K; Ohtsu K; Yamaoka H; Fukuba I; Matsuura Y; Yokoyama T Med Pediatr Oncol; 2001 Jan; 36(1):67-74. PubMed ID: 11464909 [TBL] [Abstract][Full Text] [Related]
23. Implication of unfavorable histology, MYCN amplification and diploidy for stage I and II neuroblastomas. de Buys Roessingh AS; Rougemont AL; Wiesenauer C; Barrette S; Bouron-Dal Soglio D; Lallier M Eur J Pediatr Surg; 2008 Dec; 18(6):410-4. PubMed ID: 19012235 [TBL] [Abstract][Full Text] [Related]
24. Biology of neuroblastomas that were found by mass screening at 6 months of age in Japan. Kaneko Y; Kobayashi H; Watanabe N; Tomioka N; Nakagawara A Pediatr Blood Cancer; 2006 Mar; 46(3):285-91. PubMed ID: 16078225 [TBL] [Abstract][Full Text] [Related]
25. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group. Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664 [TBL] [Abstract][Full Text] [Related]
26. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index. Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714 [TBL] [Abstract][Full Text] [Related]
27. Fluorescence in situ hybridization analysis of chromosome 1p36 deletions in human MYCN amplified neuroblastoma. Komuro H; Valentine MB; Rowe ST; Kidd VJ; Makino S; Brodeur GM; Cohn SL; Look AT J Pediatr Surg; 1998 Nov; 33(11):1695-8. PubMed ID: 9856898 [TBL] [Abstract][Full Text] [Related]
28. The genetic and clinical significance of MYCN gain as detected by FISH in neuroblastoma. Souzaki R; Tajiri T; Teshiba R; Higashi M; Kinoshita Y; Tanaka S; Taguchi T Pediatr Surg Int; 2011 Mar; 27(3):231-6. PubMed ID: 21046119 [TBL] [Abstract][Full Text] [Related]
29. Rapid and accurate determination of MYCN copy number and 1p deletion in neuroblastoma by quantitative PCR. Anderson J; Gibson S; Williamson D; Rampling D; Austin C; Shipley J; Sebire N; Brock P Pediatr Blood Cancer; 2006 Jun; 46(7):820-4. PubMed ID: 16220551 [TBL] [Abstract][Full Text] [Related]
30. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma. Chen QR; Bilke S; Wei JS; Whiteford CC; Cenacchi N; Krasnoselsky AL; Greer BT; Son CG; Westermann F; Berthold F; Schwab M; Catchpoole D; Khan J BMC Genomics; 2004 Sep; 5():70. PubMed ID: 15380028 [TBL] [Abstract][Full Text] [Related]
31. Investigation of MYCN status in neuroblastoma by fluorescence in situ hybridization. Wan TS; Ma ES; Chan GC; Chan LC Int J Mol Med; 2004 Dec; 14(6):981-7. PubMed ID: 15547663 [TBL] [Abstract][Full Text] [Related]
32. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients. Chang HH; Tseng YF; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Jou ST; Hsu WM; Jeng YM Mod Pathol; 2020 Apr; 33(4):531-540. PubMed ID: 31695155 [TBL] [Abstract][Full Text] [Related]
33. Correlation of MYCN amplification with MCM7 protein expression in neuroblastomas: a chromogenic in situ hybridization study in paraffin sections. Tsai HY; Hsi BL; Hung IJ; Yang CP; Lin JN; Chen JC; Tsai SF; Huang SF Hum Pathol; 2004 Nov; 35(11):1397-403. PubMed ID: 15668898 [TBL] [Abstract][Full Text] [Related]
34. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR. Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822 [TBL] [Abstract][Full Text] [Related]
35. Centrosome amplification is correlated with ploidy divergence, but not with MYCN amplification, in neuroblastoma tumors. Fukushi D; Watanabe N; Kasai F; Haruta M; Kikuchi A; Kikuta A; Kato K; Nakadate H; Tsunematsu Y; Kaneko Y Cancer Genet Cytogenet; 2009 Jan; 188(1):32-41. PubMed ID: 19061778 [TBL] [Abstract][Full Text] [Related]
36. The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma. Bogen D; Brunner C; Walder D; Ziegler A; Abbasi R; Ladenstein RL; Noguera R; Martinsson T; Amann G; Schilling FH; Ussowicz M; Benesch M; Ambros PF; Ambros IM Int J Cancer; 2016 Jul; 139(1):153-63. PubMed ID: 26910568 [TBL] [Abstract][Full Text] [Related]
37. Chromosome imbalances and alterations of AURKA and MYCN genes in children with neuroblastoma. Inandiklioğlu N; Yilmaz S; Demirhan O; Erdoğan S; Tanyeli A Asian Pac J Cancer Prev; 2012; 13(11):5391-7. PubMed ID: 23317189 [TBL] [Abstract][Full Text] [Related]
38. 8q deletion in MYCN-amplified neuroblastoma of a child born from assisted reproductive technology. Brassesco MS; Valera ET; de Oliveira FM; de Paula Queiroz RG; Scrideli CA; Sakamoto-Hojo ET; Tone LG J Pediatr Hematol Oncol; 2009 Mar; 31(3):215-9. PubMed ID: 19262252 [TBL] [Abstract][Full Text] [Related]
39. Constitutional 11q14-q22 chromosome deletion syndrome in a child with neuroblastoma MYCN single copy. Passariello A; De Brasi D; Defferrari R; Genesio R; Tufano M; Mazzocco K; Capasso M; Migliorati R; Martinsson T; Siani P; Nitsch L; Tonini GP Eur J Med Genet; 2013 Nov; 56(11):626-34. PubMed ID: 24035971 [TBL] [Abstract][Full Text] [Related]
40. Prognostic value of partial genetic instability in neuroblastoma with ≤50% neuroblastic cell content. Piqueras M; Navarro S; Cañete A; Castel V; Noguera R Histopathology; 2011 Jul; 59(1):22-30. PubMed ID: 21668478 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]